GFAP and glioblastoma: There is evidence that GFAP crosses the leaky BBB and is an early non-specific peripheral blood biomarker which predates the clinical diagnosis of glioblastoma.4 However, GFAP levels are too low for routine detection by commonly used protein diagnostic tests such as ELISA, and more sensitive methods for its identification are needed.5